Abstract
SCLC occurs in 10-15% of the lung cancer patient population. While patient-reported outcome (PRO) instruments exist for lung cancer, none are SCLC-specific. This study aimed to identify symptoms and impacts important to SCLC patients and develop a conceptual model that describes their experience.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have